[go: up one dir, main page]

GB9825946D0 - Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease - Google Patents

Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease

Info

Publication number
GB9825946D0
GB9825946D0 GBGB9825946.8A GB9825946A GB9825946D0 GB 9825946 D0 GB9825946 D0 GB 9825946D0 GB 9825946 A GB9825946 A GB 9825946A GB 9825946 D0 GB9825946 D0 GB 9825946D0
Authority
GB
United Kingdom
Prior art keywords
hepatitis
protease
virus
inhibition
pharmaceutical compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9825946.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Priority to GBGB9825946.8A priority Critical patent/GB9825946D0/en
Publication of GB9825946D0 publication Critical patent/GB9825946D0/en
Priority to JP2000583956A priority patent/JP2002530430A/en
Priority to AU13871/00A priority patent/AU764589B2/en
Priority to PCT/EP1999/009207 priority patent/WO2000031129A1/en
Priority to CA002352493A priority patent/CA2352493A1/en
Priority to EP99972641A priority patent/EP1144446A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9825946.8A 1998-11-26 1998-11-26 Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease Ceased GB9825946D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9825946.8A GB9825946D0 (en) 1998-11-26 1998-11-26 Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
JP2000583956A JP2002530430A (en) 1998-11-26 1999-11-24 Pharmaceutical composition for inhibiting hepatitis C virus NS3 protease
AU13871/00A AU764589B2 (en) 1998-11-26 1999-11-24 Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
PCT/EP1999/009207 WO2000031129A1 (en) 1998-11-26 1999-11-24 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
CA002352493A CA2352493A1 (en) 1998-11-26 1999-11-24 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease
EP99972641A EP1144446A1 (en) 1998-11-26 1999-11-24 Pharmaceutical compounds for the inhibition of hepatitis c virus ns3 protease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9825946.8A GB9825946D0 (en) 1998-11-26 1998-11-26 Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease

Publications (1)

Publication Number Publication Date
GB9825946D0 true GB9825946D0 (en) 1999-01-20

Family

ID=10843111

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9825946.8A Ceased GB9825946D0 (en) 1998-11-26 1998-11-26 Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease

Country Status (6)

Country Link
EP (1) EP1144446A1 (en)
JP (1) JP2002530430A (en)
AU (1) AU764589B2 (en)
CA (1) CA2352493A1 (en)
GB (1) GB9825946D0 (en)
WO (1) WO2000031129A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
MXPA04009938A (en) 2002-04-11 2004-12-13 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease.
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
ES2297424T3 (en) 2003-05-21 2008-05-01 Boehringer Ingelheim International Gmbh INHIBITING COMPOUNDS OF HEPATITIS C.
AR045596A1 (en) 2003-09-05 2005-11-02 Vertex Pharma INHIBITORS OF SERINE PROTEASES IN PARTICULAR HCV PROTEASA NS3-NS4A
DE602004031645D1 (en) 2003-09-22 2011-04-14 Boehringer Ingelheim Pharma MACROCYCLIC PEPTIDES WITH EFFECT AGAINST HEPATITIS C VIRUS
MXPA06004006A (en) 2003-10-10 2006-06-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease.
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DE602005013922D1 (en) 2004-02-24 2009-05-28 Japan Tobacco Inc CONDENSED HETEROTETRACYCLIC COMPOUNDS AND THEIR USE AS HCV POLYMERASE INHIBITOR
JP4914355B2 (en) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Hepatitis C inhibitor peptide analog
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
EP2256113A1 (en) 2005-08-02 2010-12-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CN102382170A (en) 2005-08-19 2012-03-21 弗特克斯药品有限公司 Method for preparation of protease inhibitors and intermediates
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
EP1945797B1 (en) * 2005-10-28 2012-05-30 Boehringer Ingelheim International GmbH Hepatitis c virus ns2/3 activity assay
KR20080072906A (en) 2005-11-11 2008-08-07 버텍스 파마슈티칼스 인코포레이티드 Hepatitis C Virus Variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
NZ580917A (en) 2007-05-04 2012-06-29 Vertex Pharma Combinations of protease inhibitors such as VX-950 and polymerase inhibitors for the treatment of HCV infection
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections

Also Published As

Publication number Publication date
AU1387100A (en) 2000-06-13
EP1144446A1 (en) 2001-10-17
CA2352493A1 (en) 2000-06-02
WO2000031129A1 (en) 2000-06-02
AU764589B2 (en) 2003-08-21
JP2002530430A (en) 2002-09-17

Similar Documents

Publication Publication Date Title
GB9825946D0 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
SI1169339T1 (en) Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
GB9707659D0 (en) Hepatitis C NS3 Protease inhibitors
IL191905A0 (en) Inhibitors of serine proteases particularly hepatitis c virus ns3 protease, pharmaceutical compositions containing the same and the use thereof
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
DE69929887D1 (en) Hepatitis c inhibitor peptide
HU229997B1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
PH11999002002B1 (en) Hepatitis C inhibitor tri-peptides
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
PL371324A1 (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c)
IL153669A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU1324300A (en) Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP1141255A4 (en) Modified forms of hepatitis c virus ns3 protease
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
SI1326632T1 (en) Proteasome inhibitors for the treatment of hepatitis virus infections
DE19980730D2 (en) Radioimmunopharmaceuticals for the treatment of hepatitis C

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)